Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2024 10:30 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA...
November 01, 2022 03:38 ET | Source: Allied Market Research

Global Chronic Hepatitis B (CHB) Market to Reach USD 6.1 Billion by 2031: Says AMR

Portland, OR, Nov. 01, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Chronic Hepatitis B (CHB) Market size was estimated at $4.6 billion in 2021...
August 04, 2021 07:00 ET | Source: BioNTech SE

BioNTech schließt Übernahme von Kites Neoantigen-TCR Zelltherapie-Plattform und Produktionsanlagen im amerikanischen Gaithersburg ab

MAINZ, Deutschland & Santa Monica, USA, 4. August 2021 – BioNTech SE (Nasdaq: BNTX, „BioNTech”) und Kite, ein Unternehmen der Gilead-Gruppe (Nasdaq: GILD, „Kite”) gaben heute bekannt, dass...
August 04, 2021 07:00 ET | Source: BioNTech SE

BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

MAINZ, Germany & Santa Monica, USA, August 4, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing of the acquisition of the...
March 02, 2021 10:05 ET | Source: PMI

Global Oral Solid Dosage Excipients Market estimated to be US$ 5.9 billion by 2030 with a CAGR of 7.9% during the forecast period - by PMI

Covina CA, March 02, 2021 (GLOBE NEWSWIRE) -- Global Oral Solid Dosage Excipients Market accounted for US$ 2.8 billion in 2020 and is estimated to be US$ 5.9 billion by 2030 and is anticipated to...
September 14, 2020 13:59 ET | Source: Rigrodsky & Long, P.A.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout

WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Immunomedics, Inc. (“Immunomedics”) (NASDAQ GS: IMMU) regarding possible breaches...
September 01, 2020 08:30 ET | Source: Jounce Therapeutics, Inc.

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

– Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead to Make $85 Million Upfront Payment and $35 Million Equity Investment – FOSTER CITY, Calif. and...
June 25, 2020 10:35 ET | Source: PMI

Global Rheumatoid Arthritis Therapeutics Market; High adoption of disease-modifying antirheumatic drugs (DMARDs) will boost the market - PMI

Covina, CA, June 25, 2020 (GLOBE NEWSWIRE) -- The global rheumatoid arthritis therapeutics market accounted for US$ 25.7 billion in 2019 and is estimated to be US$ 39.8 billion by 2029 and is...
April 17, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs

CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...